13
13 Key messages
Pages 77–78 · open in PDF
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 77 · PDF
Beta-blockers and ACE-I/ARNI/ARB use requires caution, individualized decisions, and close monitoring. In patients with CA and AF, anticoagulation is indicated regardless of CHA2DS2-VA score, due to high thromboembolic risk.1077,1095–1097 Transoesophageal echocardiography is necessary before cardioversion to exclude intracardiac thrombus, regardless of the duration of anticoagulation before the procedure.1098 The use of digoxin is generally discouraged due to high risk of toxicity. Few patients with CA and advanced symptoms may be eligible for heart transplantation in line with international criteria.580
reserved for fulminant, non-infectious forms of myocarditis to stabilize the patients.8
12.5. Adult congenital heart disease
Recommendation Table 28 — Recommendations for cardiac amyloidosis (see Evidence Tables 108–111) Recommendation
Treatment with a TTR silencer (vutrisiran) or with variant or wild-type transthyretin cardiac amyloidosis and NYHA classes I–III is recommended to reduce progression of symptoms and the risk of CV hospitalization and all-cause death.1082–1084 CV, cardiovascular; NYHA, New York Heart Association; TTR, transthyretin. a Class of recommendation. b Level of evidence.
12.4. Myocarditis 12.4.1. Epidemiology and diagnosis The contribution of myocarditis as a cause of HF is estimated to be less than 5%.1099 When patients with myocarditis present with DHF, LVEF <40%, life-threatening arrhythmias (ventricular tachycardia/fibrillation, third-degree atrioventricular block), and/or extensive LGE on CMR, they should be viewed as high risk.1100,1101 High-risk patients may require an endomyocardial biopsy in order to tailor treatment,8 whereas lower-risk patients may be examined with CMR imaging. The clinical presentation ranges from impaired LV function to refractory HF, CS (fulminant myocarditis), or sudden cardiac arrest. Some patients present primarily with arrhythmias. Prognosis depends on initial presentation.1100,1101 Patients with fulminant myocarditis should be transferred or discussed with a center that has the possibility to perform endomyocardial biopsy and provide MCS support. High-risk patients have a high mortality and may need temporary MCS and/or in the long term heart transplantation or durable MCS.1102–1104
12.4.2. Treatment The treatment algorithm is reported in the 2025 ESC Guidelines for the management of myocarditis and pericarditis.8 Patients with myocarditis and HFrEF should be empirically treated with FMT for HFrEF (see Section 7). Routine immunosuppression is not recommended in patients with preserved LVEF and should be
stabilizer (tafamidis or acoramidis) for patients
13. Key messages New classifications • Heart failure has been redefined with two distinct phenotypes: ⚬ HFrEF: LVEF <50% + symptoms and/or signs of HF. ⚬ HFpEF: LVEF ≥50% + symptoms and/or signs of HF + objective evidence of cardiac structural and/or functional abnormalities. • Stages of HF (A–D) have been adopted: ⚬ Stage A: individuals at risk for HF but without signs, symptoms, and cardiac abnormalities. ⚬ Stage B: pre-HF, defined as the presence of cardiac abnormalities without signs and symptoms of HF. ⚬ Stage C: symptomatic HF, defined as the presence of cardiac abnormalities and current or prior signs and/or symptoms of HF. ⚬ Stage D: advanced HF. • New classifications for medical and interventional HF therapies have been introduced. The terms are designed to be dynamic and may therefore remain contemporary over time: ⚬ FMT—Foundational medical therapy: medical therapies for unselected patients with HF with Class I recommendation for reducing HFH and/or death. ⚬ AMT—Additional medical therapy: medical therapies with Class IIa/IIb recommendations or Class I recommendations for improving symptoms/QoL or reducing morbidity or mortality in specific subsets of patients with HF. ⚬ GDIT—Guideline-directed interventional therapy: all guideline-recommended implantable devices or interventional therapies. Prevention of heart failure • A strict control of HF risk factors is recommended to prevent HF.
Adult congenital heart disease is a heterogeneous group of structural heart abnormalities varying in complexity. There has been an improvement in survival with contemporary care.1105 Consequently, HF in ACHD is increasingly common,1106,1107 and represents a major contributor to morbidity and mortality, accounting for 26%–46% of deaths, with higher rates seen in more complex lesions.1108–1110 Managing HF in ACHD poses specific challenges related to original anatomy, presence of haemodynamic lesions, previous interventions, and extracardiac complications such as kidney and liver dysfunction.1111,1112 Specific indications on the management of these patients are reported in the 2020 ESC Guidelines for the management of adult congenital heart disease1111 and in a recent ESC clinical consensus statement.1113
Page 78 · PDF
78 Diagnosis of heart failure • Measurement of natriuretic peptides and echocardiography have key roles in the diagnosis of HF. Additional testing is useful for aetiologies and phenotypes. • Multimodality aetiology assessment should be sought to find potential treatable causes of HF. Guideline-recommended therapies
Decompensated heart failure • Decompensated heart failure refers to acute or gradual onset of symptoms and/or signs of HF, severe enough to deserve urgent medical attention, leading to an unplanned hospital admission or an emergency department visit or an ambulatory visit, and requiring subsequent initiation or intensification of treatment. • Treatment of DHF is based on addressing any associated triggers urgently, diuretics for congestion with the addition of vasodilators for high blood pressure, inotropes, and/or temporary MCS for hypoperfusion. • Patients hospitalized for HF should be carefully evaluated to exclude persistent signs of congestion. FMT must be started or optimized before discharge and close visits in the early post-discharge period must be planned. Advanced heart failure • Patients with advanced HF refractory to FMT and GDIT who do not have absolute contraindications must have timely referral for consideration of heart transplantation or MCS. Cardiovascular comorbidities • Catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. Selection criteria include high-burden AF, less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF. • Patients with obstructive CAD and HF need to be treated conservatively or invasively (CABG or PCI) according to clinical and anatomical suitability for revascularization, HF phenotype and history, presence of angina, comorbidities, frailty, and patient preference. • Surgical aortic valve replacement or TAVI, as assessed by the Heart Team, is recommended in patient with severe low-flow
low-gradient aortic stenosis and HF regardless of LVEF and in patients with severe low-flow low-gradient aortic stenosis and HFrEF. • Mitral TEER is recommended in selected patients with severe ventricular secondary MR and HFrEF after optimization of FMT and CRT implantation (if needed). Non-cardiovascular comorbidities • Patients should be routinely screened and treated for non-CV comorbidities (e.g. diabetes, CKD, obesity, ID, anxiety and depression) and frailty. • Lifestyle interventions, exercise, diet, and patient education are fundamental steps for body-weight management in patients with HF and obesity, followed by pharmacological and surgical interventions. • It is recommended to switch glucose-lowering treatment from agents without proven CV efficacy or safety to agents with proven CV benefit in patients with HF and diabetes. Multidisciplinary management • A multidisciplinary HF management programme is recommended. • Cardiac rehabilitation, with exercise training, is a key tool to reduce hospitalizations and improve functional capacity and QoL in patients with HF. • Remote haemodynamic monitoring of PA pressure should be considered in selected patients; non-invasive telemonitoring modalities may be considered. Specific conditions • Pre-conception care and counselling is recommended for patients with stage B or C HF to facilitate decision-making surrounding pregnancy. • Specific disease-modifying therapies are recommended in patients with CA.
14. Gaps in evidence Despite advances in the management of HF, multiple areas of uncertainty remain. Future research should address the following gaps. (1) Definitions and prevention • Consensus regarding normal values/ranges of ejection fraction. • More information on the incidence, prevalence and prognostic importance of HF with improved LVEF, and a need to validate and evaluate the clinical importance of the new definition proposed by the Second Universal Definition of HF.47 • The benefits and risks of various weight-loss methods for HF risk reduction in obesity need further studies. • More research is needed to understand if SGLT2-Is and MRAs prevent HF in patients without diabetes but with comorbidities like obesity, hypertension, and/or CKD. • Studies are needed to better understand if CPAP therapy lowers risk of HF in patients with sleep apnoea.
• ARNIs or ACE-Is (ARB in case of intolerance) beta-blockers, MRAs, and SGLT2-Is are recommended as FMT for patients with HFrEF, whereas MRAs and SGLT2-Is are recommended as FMT for patients with HFpEF. • ICDs are recommended in selected patients with HFrEF, LVEF ≤35%, and an ischaemic aetiology, and should be considered in those with a non-ischaemic aetiology. • CRT-P or CRT-D is recommended in patients with HFrEF, LVEF ≤35%, in sinus rhythm, with an LBBB ≥150 ms and should be considered in those with an LBBB ≥130–149 ms or non-LBBB ≥150 ms.